Description: PharmAbcine, Inc., a biotechnology company, develops human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. It focuses primarily on the out-licensing of candidate therapeutics and clinical applications. The company develops TTAC0001, a human anti-angiogenic mAb against VEGFR-2(KDR); and dual specific antibody technologies, including DIG-body and PIG-body for therapeutic use. PharmAbcine, Inc. has a strategic partnership with Samsung Biologics Co.,Ltd. for the development and manufacturing of PMC-403 pipeline, a therapeutic antibody candidate to treat neovascular disorders; and a research collaboration agreement with LegoChem Biosciences Inc. (LCB) to provide PMC-403, a preclinical pipeline to LCB for a combination research using PMC-403 and LCB's ADC for solid tumors. The company is headquartered in Daejeon, South Korea.
Home Page: www.pharmabcine.com
461-8, Daejeon BioventureTown
Daejeon,
South Korea
Phone:
82 4 2863 2017
Officers
| Name | Title |
|---|---|
| Dr. Jin-San Yoo | Founder, Chief Exec. Officer, Pres and Director |
| Dr. Sang Hoon Lee | Co-Founder and Exec. VP |
| Mr. Sung Woo Kim | CFO, Director of Bus. & Director |
| Weon Sup Lee | Head of R&D Center and Director |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 503.1863 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 53 |